APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

DNA & RNA Oligonucleotides

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global DNA & RNA Oligonucleotides Market Analysis and Forecast 2026-2032

Report ID 173985310230 December 2025196 pages

Choose your research edition.

Industry ResearchDNA & RNA Oligonucleotides Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal DNA & RNA Oligonucleotides Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal DNA & RNA Oligonucleotides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DNA & RNA Oligonucleotides Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal DNA & RNA Oligonucleotides Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global DNA & RNA Oligonucleotides market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of DNA & RNA Oligonucleotides include Berry Genomics, BGI, Brooks Life Sciences, Dna Link, Eurofins Scientific, Genotypic Technology, Illumina, LabCorp and Macrogen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for DNA & RNA Oligonucleotides, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of DNA & RNA Oligonucleotides, also provides the revenue of main regions and countries. Of the upcoming market potential for DNA & RNA Oligonucleotides, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the DNA & RNA Oligonucleotides revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global DNA & RNA Oligonucleotides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for DNA & RNA Oligonucleotides revenue, projected growth trends, production technology, application and end-user industry.

DNA & RNA Oligonucleotides Segment by Company

Berry Genomics

BGI

Brooks Life Sciences

Dna Link

Eurofins Scientific

Genotypic Technology

Illumina

LabCorp

Macrogen

Natera

Roche

DNA & RNA Oligonucleotides Segment by Type

DNA Oligonucleotides

RNA Oligonucleotides

DNA & RNA Oligonucleotides Segment by Application

Biopharma Companies

Academic & Research Organizations

Hospitals and Clinics

Others

DNA & RNA Oligonucleotides Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA & RNA Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DNA & RNA Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA & RNA Oligonucleotides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of DNA & RNA Oligonucleotides in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of DNA & RNA Oligonucleotides company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, DNA & RNA Oligonucleotides revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global DNA & RNA Oligonucleotides Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DNA Oligonucleotides Major Player Table 3. RNA Oligonucleotides Major Player Table 4. Global DNA & RNA Oligonucleotides Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Biopharma Companies Major Player Table 6. Academic & Research Organizations Major Player Table 7. Hospitals and Clinics Major Player Table 8. Others Major Player Table 9. DNA & RNA Oligonucleotides Industry Trends Table 10. DNA & RNA Oligonucleotides Industry Drivers Table 11. DNA & RNA Oligonucleotides Industry Opportunities and Challenges Table 12. DNA & RNA Oligonucleotides Industry Restraints Table 13. Global DNA & RNA Oligonucleotides Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global DNA & RNA Oligonucleotides Market Size by Region (2021-2026) & (US$ Million) Table 15. Global DNA & RNA Oligonucleotides Market Share by Region (2021-2026) Table 16. Global DNA & RNA Oligonucleotides Market Size by Region (2027-2032) & (US$ Million) Table 17. Global DNA & RNA Oligonucleotides Market Share by Region (2027-2032) Table 18. Global DNA & RNA Oligonucleotides Revenue by Players (US$ Million) & (2021-2026) Table 19. Global DNA & RNA Oligonucleotides Revenue Market Share by Players (2021-2026) Table 20. Global DNA & RNA Oligonucleotides Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global DNA & RNA Oligonucleotides Key Players Headquarters & Area Served Table 22. Global DNA & RNA Oligonucleotides Players, Product Type & Application Table 23. Global DNA & RNA Oligonucleotides Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global DNA & RNA Oligonucleotides by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global DNA & RNA Oligonucleotides Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global DNA & RNA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 28. Global DNA & RNA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 29. Global DNA & RNA Oligonucleotides Revenue Market Share by Type (2021-2026) Table 30. Global DNA & RNA Oligonucleotides Revenue Market Share by Type (2027-2032) Table 31. Global DNA & RNA Oligonucleotides Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global DNA & RNA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 33. Global DNA & RNA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 34. Global DNA & RNA Oligonucleotides Revenue Market Share by Application (2021-2026) Table 35. Global DNA & RNA Oligonucleotides Revenue Market Share by Application (2027-2032) Table 36. Berry Genomics Company Information Table 37. Berry Genomics Business Overview Table 38. Berry Genomics DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Berry Genomics DNA & RNA Oligonucleotides Product Portfolio Table 40. Berry Genomics Recent Development Table 41. BGI Company Information Table 42. BGI Business Overview Table 43. BGI DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. BGI DNA & RNA Oligonucleotides Product Portfolio Table 45. BGI Recent Development Table 46. Brooks Life Sciences Company Information Table 47. Brooks Life Sciences Business Overview Table 48. Brooks Life Sciences DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Brooks Life Sciences DNA & RNA Oligonucleotides Product Portfolio Table 50. Brooks Life Sciences Recent Development Table 51. Dna Link Company Information Table 52. Dna Link Business Overview Table 53. Dna Link DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Dna Link DNA & RNA Oligonucleotides Product Portfolio Table 55. Dna Link Recent Development Table 56. Eurofins Scientific Company Information Table 57. Eurofins Scientific Business Overview Table 58. Eurofins Scientific DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Eurofins Scientific DNA & RNA Oligonucleotides Product Portfolio Table 60. Eurofins Scientific Recent Development Table 61. Genotypic Technology Company Information Table 62. Genotypic Technology Business Overview Table 63. Genotypic Technology DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Genotypic Technology DNA & RNA Oligonucleotides Product Portfolio Table 65. Genotypic Technology Recent Development Table 66. Illumina Company Information Table 67. Illumina Business Overview Table 68. Illumina DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Illumina DNA & RNA Oligonucleotides Product Portfolio Table 70. Illumina Recent Development Table 71. LabCorp Company Information Table 72. LabCorp Business Overview Table 73. LabCorp DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. LabCorp DNA & RNA Oligonucleotides Product Portfolio Table 75. LabCorp Recent Development Table 76. Macrogen Company Information Table 77. Macrogen Business Overview Table 78. Macrogen DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Macrogen DNA & RNA Oligonucleotides Product Portfolio Table 80. Macrogen Recent Development Table 81. Natera Company Information Table 82. Natera Business Overview Table 83. Natera DNA & RNA Oligonucleotides Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Natera DNA & RNA Oligonucleotides Product Portfolio Table 85. Natera Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche DNA & RNA Oligonucleotides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche DNA & RNA Oligonucleotides Product Portfolio Table 90. Roche Recent Development Table 91. North America DNA & RNA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 92. North America DNA & RNA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 93. North America DNA & RNA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 94. North America DNA & RNA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 95. North America DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America DNA & RNA Oligonucleotides Revenue by Country (2021-2026) & (US$ Million) Table 97. North America DNA & RNA Oligonucleotides Revenue by Country (US$ Million) & (2027-2032) Table 98. Europe DNA & RNA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 99. Europe DNA & RNA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 100. Europe DNA & RNA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe DNA & RNA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe DNA & RNA Oligonucleotides Revenue by Country (2021-2026) & (US$ Million) Table 104. Europe DNA & RNA Oligonucleotides Revenue by Country (US$ Million) & (2027-2032) Table 105. China DNA & RNA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 106. China DNA & RNA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 107. China DNA & RNA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 108. China DNA & RNA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia DNA & RNA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 110. Asia DNA & RNA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 111. Asia DNA & RNA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 112. Asia DNA & RNA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia DNA & RNA Oligonucleotides Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia DNA & RNA Oligonucleotides Revenue by Region (US$ Million) & (2021-2026) Table 115. Asia DNA & RNA Oligonucleotides Revenue by Region (US$ Million) & (2027-2032) Table 116. SAMEA DNA & RNA Oligonucleotides Revenue by Type (2021-2026) & (US$ Million) Table 117. SAMEA DNA & RNA Oligonucleotides Revenue by Type (2027-2032) & (US$ Million) Table 118. SAMEA DNA & RNA Oligonucleotides Revenue by Application (2021-2026) & (US$ Million) Table 119. SAMEA DNA & RNA Oligonucleotides Revenue by Application (2027-2032) & (US$ Million) Table 120. SAMEA DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. SAMEA DNA & RNA Oligonucleotides Revenue by Country (2021-2026) & (US$ Million) Table 122. SAMEA DNA & RNA Oligonucleotides Revenue by Country (US$ Million) & (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. DNA & RNA Oligonucleotides Image Figure 2. Global DNA & RNA Oligonucleotides Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DNA & RNA Oligonucleotides Market Size Share 2021 VS 2025 VS 2032 Figure 4. DNA Oligonucleotides Image Figure 5. RNA Oligonucleotides Image Figure 6. Global DNA & RNA Oligonucleotides Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global DNA & RNA Oligonucleotides Market Size Share 2021 VS 2025 VS 2032 Figure 8. Biopharma Companies Image Figure 9. Academic & Research Organizations Image Figure 10. Hospitals and Clinics Image Figure 11. Others Image Figure 12. Global DNA & RNA Oligonucleotides Market Size (US$ Million) & (2021-2032) Figure 13. Global DNA & RNA Oligonucleotides Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global DNA & RNA Oligonucleotides Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global DNA & RNA Oligonucleotides Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global DNA & RNA Oligonucleotides Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global DNA & RNA Oligonucleotides Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global DNA & RNA Oligonucleotides Revenue Market Share by Type (2021-2032) Figure 20. Global DNA & RNA Oligonucleotides Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global DNA & RNA Oligonucleotides Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global DNA & RNA Oligonucleotides Revenue Market Share by Application (2021-2032) Figure 23. North America DNA & RNA Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032) Figure 25. North America DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032) Figure 26. North America DNA & RNA Oligonucleotides Revenue Share by Country (2021-2032) Figure 27. United States DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe DNA & RNA Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032) Figure 32. Europe DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032) Figure 33. Europe DNA & RNA Oligonucleotides Revenue Share by Country (2021-2032) Figure 34. Germany DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China DNA & RNA Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032) Figure 44. China DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032) Figure 45. Asia DNA & RNA Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032) Figure 47. Asia DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032) Figure 48. Asia DNA & RNA Oligonucleotides Revenue Share by Region (2021-2032) Figure 49. Japan DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA DNA & RNA Oligonucleotides Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032) Figure 57. SAMEA DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032) Figure 58. SAMEA DNA & RNA Oligonucleotides Revenue Share by Country (2021-2032) Figure 59. Brazil DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt DNA & RNA Oligonucleotides Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Oligonucleotides
  • RNA Oligonucleotides
Applications
  • Biopharma Companies
  • Academic & Research Organizations
  • Hospitals and Clinics
  • Others
Companies covered
  • Berry Genomics
  • BGI
  • Brooks Life Sciences
  • Dna Link
  • Eurofins Scientific
  • Genotypic Technology
  • Illumina
  • LabCorp
  • Macrogen
  • Natera
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 DNA & RNA Oligonucleotides Market by Type
  3. 1.2.1 Global DNA & RNA Oligonucleotides Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DNA Oligonucleotides
  5. 1.2.3 RNA Oligonucleotides
  6. 1.3 DNA & RNA Oligonucleotides Market by Application
  7. 1.3.1 Global DNA & RNA Oligonucleotides Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Biopharma Companies
  9. 1.3.3 Academic & Research Organizations
  10. 1.3.4 Hospitals and Clinics
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 DNA & RNA Oligonucleotides Market Dynamics
  1. 2.1 DNA & RNA Oligonucleotides Industry Trends
  2. 2.2 DNA & RNA Oligonucleotides Industry Drivers
  3. 2.3 DNA & RNA Oligonucleotides Industry Opportunities and Challenges
  4. 2.4 DNA & RNA Oligonucleotides Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global DNA & RNA Oligonucleotides Market Perspective (2021-2032)
  2. 3.2 Global DNA & RNA Oligonucleotides Growth Trends by Region
  3. 3.2.1 Global DNA & RNA Oligonucleotides Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global DNA & RNA Oligonucleotides Market Size by Region (2021-2026)
  5. 3.2.3 Global DNA & RNA Oligonucleotides Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global DNA & RNA Oligonucleotides Revenue by Players
  2. 4.1.1 Global DNA & RNA Oligonucleotides Revenue by Players (2021-2026)
  3. 4.1.2 Global DNA & RNA Oligonucleotides Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global DNA & RNA Oligonucleotides Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global DNA & RNA Oligonucleotides Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global DNA & RNA Oligonucleotides Key Players Headquarters & Area Served
  7. 4.4 Global DNA & RNA Oligonucleotides Players, Product Type & Application
  8. 4.5 Global DNA & RNA Oligonucleotides Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global DNA & RNA Oligonucleotides Market CR5 and HHI
  11. 4.6.3 2025 DNA & RNA Oligonucleotides Tier 1, Tier 2, and Tier 3
5 DNA & RNA Oligonucleotides Market Size by Type
  1. 5.1 Global DNA & RNA Oligonucleotides Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global DNA & RNA Oligonucleotides Revenue by Type (2021-2032)
  3. 5.3 Global DNA & RNA Oligonucleotides Revenue Market Share by Type (2021-2032)
6 DNA & RNA Oligonucleotides Market Size by Application
  1. 6.1 Global DNA & RNA Oligonucleotides Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global DNA & RNA Oligonucleotides Revenue by Application (2021-2032)
  3. 6.3 Global DNA & RNA Oligonucleotides Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Berry Genomics
  2. 7.1.1 Berry Genomics Company Information
  3. 7.1.2 Berry Genomics Business Overview
  4. 7.1.3 Berry Genomics DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Berry Genomics DNA & RNA Oligonucleotides Product Portfolio
  6. 7.1.5 Berry Genomics Recent Developments
  7. 7.2 BGI
  8. 7.2.1 BGI Company Information
  9. 7.2.2 BGI Business Overview
  10. 7.2.3 BGI DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BGI DNA & RNA Oligonucleotides Product Portfolio
  12. 7.2.5 BGI Recent Developments
  13. 7.3 Brooks Life Sciences
  14. 7.3.1 Brooks Life Sciences Company Information
  15. 7.3.2 Brooks Life Sciences Business Overview
  16. 7.3.3 Brooks Life Sciences DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Brooks Life Sciences DNA & RNA Oligonucleotides Product Portfolio
  18. 7.3.5 Brooks Life Sciences Recent Developments
  19. 7.4 Dna Link
  20. 7.4.1 Dna Link Company Information
  21. 7.4.2 Dna Link Business Overview
  22. 7.4.3 Dna Link DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Dna Link DNA & RNA Oligonucleotides Product Portfolio
  24. 7.4.5 Dna Link Recent Developments
  25. 7.5 Eurofins Scientific
  26. 7.5.1 Eurofins Scientific Company Information
  27. 7.5.2 Eurofins Scientific Business Overview
  28. 7.5.3 Eurofins Scientific DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eurofins Scientific DNA & RNA Oligonucleotides Product Portfolio
  30. 7.5.5 Eurofins Scientific Recent Developments
  31. 7.6 Genotypic Technology
  32. 7.6.1 Genotypic Technology Company Information
  33. 7.6.2 Genotypic Technology Business Overview
  34. 7.6.3 Genotypic Technology DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Genotypic Technology DNA & RNA Oligonucleotides Product Portfolio
  36. 7.6.5 Genotypic Technology Recent Developments
  37. 7.7 Illumina
  38. 7.7.1 Illumina Company Information
  39. 7.7.2 Illumina Business Overview
  40. 7.7.3 Illumina DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Illumina DNA & RNA Oligonucleotides Product Portfolio
  42. 7.7.5 Illumina Recent Developments
  43. 7.8 LabCorp
  44. 7.8.1 LabCorp Company Information
  45. 7.8.2 LabCorp Business Overview
  46. 7.8.3 LabCorp DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  47. 7.8.4 LabCorp DNA & RNA Oligonucleotides Product Portfolio
  48. 7.8.5 LabCorp Recent Developments
  49. 7.9 Macrogen
  50. 7.9.1 Macrogen Company Information
  51. 7.9.2 Macrogen Business Overview
  52. 7.9.3 Macrogen DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Macrogen DNA & RNA Oligonucleotides Product Portfolio
  54. 7.9.5 Macrogen Recent Developments
  55. 7.10 Natera
  56. 7.10.1 Natera Company Information
  57. 7.10.2 Natera Business Overview
  58. 7.10.3 Natera DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Natera DNA & RNA Oligonucleotides Product Portfolio
  60. 7.10.5 Natera Recent Developments
  61. 7.11 Roche
  62. 7.11.1 Roche Company Information
  63. 7.11.2 Roche Business Overview
  64. 7.11.3 Roche DNA & RNA Oligonucleotides Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Roche DNA & RNA Oligonucleotides Product Portfolio
  66. 7.11.5 Roche Recent Developments
8 North America
  1. 8.1 North America DNA & RNA Oligonucleotides Revenue (2021-2032)
  2. 8.2 North America DNA & RNA Oligonucleotides Revenue by Type (2021-2032)
  3. 8.2.1 North America DNA & RNA Oligonucleotides Revenue by Type (2021-2026)
  4. 8.2.2 North America DNA & RNA Oligonucleotides Revenue by Type (2027-2032)
  5. 8.3 North America DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032)
  6. 8.4 North America DNA & RNA Oligonucleotides Revenue by Application (2021-2032)
  7. 8.4.1 North America DNA & RNA Oligonucleotides Revenue by Application (2021-2026)
  8. 8.4.2 North America DNA & RNA Oligonucleotides Revenue by Application (2027-2032)
  9. 8.5 North America DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032)
  10. 8.6 North America DNA & RNA Oligonucleotides Revenue by Country
  11. 8.6.1 North America DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America DNA & RNA Oligonucleotides Revenue by Country (2021-2026)
  13. 8.6.3 North America DNA & RNA Oligonucleotides Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe DNA & RNA Oligonucleotides Revenue (2021-2032)
  2. 9.2 Europe DNA & RNA Oligonucleotides Revenue by Type (2021-2032)
  3. 9.2.1 Europe DNA & RNA Oligonucleotides Revenue by Type (2021-2026)
  4. 9.2.2 Europe DNA & RNA Oligonucleotides Revenue by Type (2027-2032)
  5. 9.3 Europe DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032)
  6. 9.4 Europe DNA & RNA Oligonucleotides Revenue by Application (2021-2032)
  7. 9.4.1 Europe DNA & RNA Oligonucleotides Revenue by Application (2021-2026)
  8. 9.4.2 Europe DNA & RNA Oligonucleotides Revenue by Application (2027-2032)
  9. 9.5 Europe DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032)
  10. 9.6 Europe DNA & RNA Oligonucleotides Revenue by Country
  11. 9.6.1 Europe DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe DNA & RNA Oligonucleotides Revenue by Country (2021-2026)
  13. 9.6.3 Europe DNA & RNA Oligonucleotides Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China DNA & RNA Oligonucleotides Revenue (2021-2032)
  2. 10.2 China DNA & RNA Oligonucleotides Revenue by Type (2021-2032)
  3. 10.2.1 China DNA & RNA Oligonucleotides Revenue by Type (2021-2026)
  4. 10.2.2 China DNA & RNA Oligonucleotides Revenue by Type (2027-2032)
  5. 10.3 China DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032)
  6. 10.4 China DNA & RNA Oligonucleotides Revenue by Application (2021-2032)
  7. 10.4.1 China DNA & RNA Oligonucleotides Revenue by Application (2021-2026)
  8. 10.4.2 China DNA & RNA Oligonucleotides Revenue by Application (2027-2032)
  9. 10.5 China DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia DNA & RNA Oligonucleotides Revenue (2021-2032)
  2. 11.2 Asia DNA & RNA Oligonucleotides Revenue by Type (2021-2032)
  3. 11.2.1 Asia DNA & RNA Oligonucleotides Revenue by Type (2021-2026)
  4. 11.2.2 Asia DNA & RNA Oligonucleotides Revenue by Type (2027-2032)
  5. 11.3 Asia DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032)
  6. 11.4 Asia DNA & RNA Oligonucleotides Revenue by Application (2021-2032)
  7. 11.4.1 Asia DNA & RNA Oligonucleotides Revenue by Application (2021-2026)
  8. 11.4.2 Asia DNA & RNA Oligonucleotides Revenue by Application (2027-2032)
  9. 11.5 Asia DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032)
  10. 11.6 Asia DNA & RNA Oligonucleotides Revenue by Country
  11. 11.6.1 Asia DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia DNA & RNA Oligonucleotides Revenue by Country (2021-2026)
  13. 11.6.3 Asia DNA & RNA Oligonucleotides Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA DNA & RNA Oligonucleotides Revenue (2021-2032)
  2. 12.2 SAMEA DNA & RNA Oligonucleotides Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA DNA & RNA Oligonucleotides Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA DNA & RNA Oligonucleotides Revenue by Type (2027-2032)
  5. 12.3 SAMEA DNA & RNA Oligonucleotides Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA DNA & RNA Oligonucleotides Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA DNA & RNA Oligonucleotides Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA DNA & RNA Oligonucleotides Revenue by Application (2027-2032)
  9. 12.5 SAMEA DNA & RNA Oligonucleotides Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA DNA & RNA Oligonucleotides Revenue by Country
  11. 12.6.1 SAMEA DNA & RNA Oligonucleotides Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA DNA & RNA Oligonucleotides Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA DNA & RNA Oligonucleotides Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst